Patient-Derived Gastric Cancer Assembloids Reveal Stromal Influence

Study Background and Research Question

Gastric cancer remains a significant clinical challenge, ranking as the fifth most common malignancy and the second leading cause of cancer-related mortality globally. Despite multimodal treatment strategies—including surgery, chemotherapy, radiotherapy, and targeted or immune-based therapies—patients with advanced or metastatic disease face a five-year survival rate below 10%. The heterogeneity of gastric tumors and the complexity of their microenvironment contribute to variable treatment responses and poor prognoses. Existing in vitro tumor models, especially conventional three-dimensional organoid cultures, often fail to capture the full spectrum of tumor–stroma interactions that are central to cancer progression and drug resistance. This gap complicates efforts to predict therapeutic responses and develop effective, personalized treatments.

Addressing this challenge, the reference study (Shapira-Netanelov et al., 2025) sought to create a more physiologically relevant in vitro model by integrating patient-matched tumor organoids with diverse stromal cell subpopulations. The aim was to better recapitulate the complexity of the tumor microenvironment and enable more accurate preclinical assessment of drug responses and resistance mechanisms.

Key Innovation from the Reference Study

The study's principal innovation is the development of a gastric cancer assembloid model that combines epithelial tumor organoids with autologous stromal cell subpopulations, all derived from the same patient tissue. Unlike previous organoid models, which typically lack the cellular diversity and signaling context of in vivo tumors, these assembloids incorporate mesenchymal stem cells, fibroblasts, and endothelial cells in a single co-culture system. This integration yields a multicellular structure that preserves both the epithelial and stromal complexity of primary tumors, offering a more robust platform for investigating tumor–stroma interactions.

Importantly, the assembloid system enables detailed study of how stromal components modulate gene expression, extracellular matrix remodeling, inflammatory signaling, and, crucially, drug sensitivity. The model provides insights that are unattainable in monoculture organoid systems, enhancing its value for translational cancer biology and personalized therapy research (reference study).

Methods and Experimental Design Insights

The researchers established the gastric cancer assembloid model through several key methodological steps:

• Tumor tissue from gastric cancer patients was enzymatically dissociated to obtain single-cell suspensions.
• These suspensions were expanded in tailored media to isolate and propagate distinct cell populations: epithelial organoids, mesenchymal stem cells, fibroblasts, and endothelial cells.
• The various cell types, derived from the same patient (autologous), were recombined in an optimized co-culture medium designed to support the growth and viability of each subpopulation.
• Assembloids were characterized by immunofluorescence staining for epithelial and stromal markers and by transcriptomic profiling via RNA sequencing.
• Drug response was assessed using cell viability assays following treatment with a panel of therapeutic agents, allowing comparative analysis between assembloid and monoculture models.

This design ensured that the assembloids retained the genetic and phenotypic diversity of the original tumor, including key stromal features implicated in therapy resistance and cancer progression.

Protocol Parameters

• Tumor dissociation: Enzymatic digestion of fresh tissue using collagenase and DNase for single-cell suspension preparation.
• Cell expansion: Use of lineage-specific growth media for organoids, mesenchymal stem cells, fibroblasts, and endothelial cells, adjusted for each cell type's requirements.
• Co-culture assembly: Combination of organoid and stromal cells at optimized ratios in assembloid medium; exact ratios tailored to reflect patient tumor composition.
• Characterization: Immunofluorescence staining for cytokeratins (epithelial markers) and vimentin/fibronectin (stromal markers); RNA-seq for transcriptome profiling.
• Drug screening: Cell viability assays performed after 72 hours of drug exposure; response compared between assembloid and monoculture settings.

Core Findings and Why They Matter

The primary assembloid cultures successfully recapitulated the cellular heterogeneity of patient tumors, as demonstrated by the co-expression of epithelial and stromal markers. Transcriptomic analysis revealed that assembloids exhibited higher expression of inflammatory cytokines, extracellular matrix remodeling genes, and tumor progression signatures compared to monocultures. These findings indicate that stromal components play a non-redundant role in shaping the biological behavior of gastric cancer cells.

Drug screening experiments highlighted significant variability in response, both between patients and among different drugs. Notably, several agents that were effective in monoculture organoids lost efficacy in the assembloid system, underscoring the modulatory influence of stromal populations on therapeutic sensitivity. This observation aligns with clinical experience, where tumor microenvironment-driven resistance frequently limits the success of targeted therapy research and underscores the importance of physiologically relevant models for preclinical evaluation (reference study).

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on the value of advanced in vitro models and targeted inhibitors in cancer biology research. For example, the review "Afatinib in Complex Tumor Microenvironment Modeling: Beyond Monolayers" (internal article) emphasizes the utility of Afatinib (BIBW 2992), an irreversible ErbB family tyrosine kinase inhibitor, in dissecting EGFR, HER2, and HER4-driven pathways within assembloid and organoid systems. This aligns closely with the reference paper's focus on reproducing the tumor microenvironment to study drug resistance mechanisms.

Additionally, "Afatinib: Advancing Cancer Biology Research with Irreversible Kinase Inhibition" (internal article) discusses how the irreversible inhibition profile of Afatinib supports high-fidelity modeling of clinical resistance mutations, such as T790M in EGFR, and underscores the value of integrating such inhibitors into assembloid workflows. These resources collectively reinforce the importance of using physiologically relevant models to accurately evaluate the complexities of EGFR signaling pathway inhibition, HER2 and HER4 kinase inhibition, and drug resistance in cancer biology research.

Limitations and Transferability

Despite its marked advances, the gastric cancer assembloid model has several limitations. The co-culture conditions, while optimized, may not fully recapitulate in vivo stromal diversity or the influence of immune cells, which also play a significant role in tumor progression and therapy response. The scalability of patient-specific assembloid generation for large-scale drug screening remains to be demonstrated. In addition, while the study's approach is directly applicable to gastric cancer, its transferability to other tumor types will require adaptation to the specific cellular and microenvironmental context of those malignancies.

Nevertheless, this model represents a substantial step toward bridging the gap between simplified in vitro systems and the complex biology of patient tumors, offering new avenues to study targeted therapy research and resistance phenomena.

Research Support Resources

For researchers seeking to implement similar assembloid systems or to interrogate ErbB receptor signaling in complex tumor microenvironments, the use of irreversible kinase inhibitors such as Afatinib (SKU A4746) is well supported by both the reference study and related literature. Afatinib (also known as BIBW 2992) covalently inhibits EGFR, HER2, and HER4, making it a valuable pharmacological tool in cancer biology research and drug resistance modeling (see internal guide). APExBIO supplies Afatinib with validated purity and stability for research purposes; researchers should strictly observe recommended storage and handling protocols to ensure experimental reliability. These resources collectively facilitate reproducible, mechanistically insightful studies in tumor–stroma interaction and targeted therapy research.